Febuxostat: beyond uric acid lowering Renal, c...

Elevated serum urate is linked to hypertension, insulin resistance, chronic kidney disease, and cardiovascular disease.⁵ Rather than merely marking disease, hyperuricemia may actively drive these conditions. Recent trials—FEATHER, FREED, and SIRCAR—demonstrate febuxostat slows kidney disease progression in advanced CKD.^7-9 Its hepatic clearance makes it ideal for patients with renal limitations who cannot tolerate allopurinol. The CARES and FAST trials confirm cardiovascular safety comparable to allopurinol.^10-12

This article explores febuxostat's role in managing the constellation of cardiorenal and metabolic risks associated with hyperuricemia. Click on the link below to read more.

^{References: 1. Komoriya K et al. Nucleosides Nucleotides Nucleic Acids. 2004;23(8–9):1119–1122. 2. FitzGerald JD et al. Arthritis Care Res (Hoboken). 2020;72(6):744–760. 3. Kakimoto M et al. J Appl Biomed. 2023;21(2):80–90. 4. Teragawa H et al. Clin Cardiol.2023;46(6):698–706. 5. Feig DI et al. N Engl J Med. 2008;359(17):1811–1821. 6. Li L et al. BMC Nephrol. 2014;15:122. 7. Kimura K et al. Am J Kidney Dis. 2018;72(6):798–810. 8. Kojima S et al. Rheumatology (Oxford). 2022;61(6):2346–2359. 9. Sircar D et al. Am J KidneyDis. 2015;66(6):945–950. 10. White WB et al. N Engl J Med. 2018;378(13):1200–1210. 11. Choi HK et al. Arthritis Rheumatol. 2018;70(11):1702–1709. 12. Mackenzie IS et al. Lancet. 2020;396(10264):1745–1757.}

Febuxostat: beyond uric acid lowering Renal, cardiovascular, and metabolic implications

Resources

Febulitt Advertorial

Febulitt Advertorial